Cambridge Investment Research Advisors’s NeuroOne Medical Technologies NMTC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$133K	Hold	28,500	–	–	﹤0.01%	3752
2025 Q4	$130K	Buy	28,500 +8,333	+41%	+$38K	﹤0.01%	3664
2025 Q3	$108K	Buy	20,167 +6,667	+49%	+$32.6K	﹤0.01%	3584
2025 Q2	$55K	Hold	13,500	–	–	﹤0.01%	3533
2025 Q1	$69K	Buy	+13,500	New	+$85.7K	﹤0.01%	3385
2024 Q3	–	Sell	-1,733	Closed	-$8K	–	3493
2024 Q2	$8K	Buy	+1,733	New	+$10.9K	﹤0.01%	3298

Other funds holding NMTC

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors's NMTC Position: Q1 2026 in Review

Cambridge Investment Research Advisors held its NeuroOne Medical Technologies (NMTC) position steady in Q1 2026 at 28,500 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #3752.

Cambridge Investment Research Advisors first reported a position in NMTC in Q2 2024 and has held it in 6 quarters since. 32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

Cambridge Investment Research Advisors held 28,500 shares of NeuroOne Medical Technologies worth $133K as of Q1 2026.
Cambridge Investment Research Advisors left its NeuroOne Medical Technologies share count unchanged in Q1 2026.
NeuroOne Medical Technologies made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3752 holding.
Cambridge Investment Research Advisors first reported a position in NeuroOne Medical Technologies in Q2 2024 and has held it in 6 quarters since.
32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.